Theralase® Technologies Inc.

Theralase®: Advancing Personalized Anti-Cancer Therapy

🇨🇦 TSXV: $TLT.V | 🇺🇸 OTCQB: $TLTFF

[Theralase® Technologies Inc. @TheralaseTech]

Researchers from 3 universities are engineering light-activated smart nanoparticles to treat brain cancer.

At Theralase®, we welcome continued research into light-activated cancer treatments like our drug Ruvidar®.

More on Ruvidar®: https://t.co/M2JttiMn9g

🇨🇦 $TLT.V 🇺🇸 #TLTFF

[Theralase® Technologies Inc. @TheralaseTech]

Our investigational cancer treatment Ruvidar® has a very high safety profile, sparing patients from collateral damage and a lot of quality-of-life issues related to cancer treatments, CEO Roger White told Stocks to Watch.

See more: https://t.co/i4JhhWv7UP

🇨🇦 $TLT.V 🇺🇸 #TLTFF

[Theralase® Technologies Inc. @TheralaseTech]

📢 NEWS RELEASE: Good Laboratory Practice (GLP) toxicology analysis of intravenously administered Rutherrin® has begun.

Rutherrin® has preclinically demonstrated the ability to target & destroy cancer cells after energy activation.

Read: https://t.co/Wp45Sxcrpj

$TLT.V #TLTFF

[Theralase® Technologies Inc. @TheralaseTech]

Positive interim clinical data from our Ruvidar® study support our planned next steps, including additional clinical studies and regulatory submissions.

Find out more about our anti-cancer treatment: https://t.co/FlQhNtOUdZ

🇨🇦 $TLT.V 🇺🇸 #TLTFF

[Theralase® Technologies Inc. @TheralaseTech]

Ruvidar® represents one of the technologies reshaping cancer treatment.

Frontiers recently covered photonic cancer treatments, which use interactions between light and matter to destroy tumors with less collateral damage.

Read: https://t.co/yGn0FJdGNU

🇨🇦 $TLT.V 🇺🇸 #TLTFF

[Theralase® Technologies Inc. @TheralaseTech]

Theralase® shared its Q2 2026 financial, clinical, and operational update, including interim Study 2 data for Ruvidar®, planned regulatory submissions, recent financing, and pipeline progress.

Watch: https://t.co/sAF5Vw3xof

$TLT.V #TLTFF

[Stocks to Watch @stocks2watch_]

.@TheralaseTech ( $TLT.V | #TLTFF ) is advancing a light-activated approach to treating BCG-unresponsive bladder cancer. CEO Roger Dumoulin-White discusses Ruvidar®’s Phase II progress and its drug-light activation system.

Watch: https://t.co/4FPImg0dF9

[Theralase® Technologies Inc. @TheralaseTech]

Ruvidar® exploits how cells absorb iron to destroy cancer cells.

Cancer cells need more iron than healthy cells, so they have more iron-absorbing receptors. They end up retaining Ruvidar®, which destroys them once activated.

More: https://t.co/OXuwpoOs3G

$TLT.V #TLTFF

[Theralase® Technologies Inc. @TheralaseTech]

Ruvidar® is our investigational, light-activated, ruthenium-based cancer treatment.

In our Phase II study, 95 patients with non-muscle-invasive bladder cancer enrolled for treatment. The interim clinical data are promising.

More: https://t.co/vXyXH7bysf

🇨🇦 $TLT.V 🇺🇸 #TLTFF

[Theralase® Technologies Inc. @TheralaseTech]

Theralase® will host a conference call today, September 3 at 11:00 AM ET to present its financial and operational results for Q2 2026. Hear the latest updates on the company’s progress during the quarter.

Join us at: https://t.co/thDtNeb1cO

🇨🇦 $TLT.V 🇺🇸 #TLTFF

[Theralase® Technologies Inc. @TheralaseTech]

At our annual meeting last June, Theralase® discussed the successful clinical trials for Ruvidar®, along with updates on planned cancer studies, our collaboration with Ferring Pharmaceuticals, and our future outlook.

Watch: https://t.co/JBEXHgIcAJ

🇨🇦 $TLT.V 🇺🇸 #TLTFF

[Theralase® Technologies Inc. @TheralaseTech]

We have released our Q2 2026 financial statements and updates on our Phase II bladder cancer clinical study and oncology pipeline. We’ll discuss our financial and operational results during a conference call on Sept. 3 at 11 AM ET.

Read: https://t.co/vXyXH7c6hN

$TLT.V #TLTFF

[Stocks to Watch @stocks2watch_]

.@TheralaseTech ( $TLT | #TLTFF ) CEO Roger White provides an update on the company’s light-activated small-molecule technology and its development for non-muscle-invasive bladder cancer.

Watch: https://t.co/74LCko0HvO

[Theralase® Technologies Inc. @TheralaseTech]

Ruvidar® is made in compliance with regulatory quality standards in Canada and the U.S.

The molecule has a 10-year shelf life at room temperature. It's also extremely potent; only 1/2 gram is required to treat bladder cancer.

More: https://t.co/EWY8oEsy11

🇨🇦 $TLT.V 🇺🇸 #TLTFF

[Theralase® Technologies Inc. @TheralaseTech]

Theralase® Technologies has closed its brokered private placement, raising gross proceeds of over C$3.5M to support GLP toxicology studies, working capital, and general corporate purposes.

For more info: https://t.co/oUFgIXntPa

🇨🇦 $TLT.V 🇺🇸 #TLTFF

[Theralase® Technologies Inc. @TheralaseTech]

NEWS ALERT: Theralase® Demonstrates Proof-of-Concept for Canadian-Made COVID-19 Vaccine
#COVID19 #theralase #COVIDCanada

Read more: https://t.co/IjFVoNlGRZ

[Theralase® Technologies Inc. @TheralaseTech]

NEWS ALERT: Theralase® Expands Intellectual Property Portfolio

#cancerresearch #theralase

Read more: https://t.co/TkPCnrjDdS

[Theralase® Technologies Inc. @TheralaseTech]

We are pleased to release the Company Newsletter for the third quarter of 2021. The Newsletter provides updates on the previous quarter and the progress on the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study.

Read the full newsletter: https://t.co/5owVoUYeKM

[Theralase® Technologies Inc. @TheralaseTech]

Efficacy of low-level laser therapy on pain and disability in knee osteoarthritis: systematic review and meta-analysis of randomized placebo-controlled trials - https://t.co/rfRDIifZ2v

[Theralase® Technologies Inc. @TheralaseTech]

NEWS ALERT: Theralase® Launches Seventh US-Based Clinical Study Site at and Treats First Patient in the US.

Read More: https://t.co/wbSTjUXvC7